Salim Syed
Stock Analyst at Mizuho
(0)
# 3478
Out of 5,218 analysts
76
Total ratings
38.89%
Success rate
0.42%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
WAVE Life Sciences | Maintains: Outperform | 19 22 | 13.43 | 63.81% | 5 | Nov 21, 2024 | |
Nkarta | Maintains: Outperform | 20 16 | 2.35 | 580.85% | 7 | Nov 21, 2024 | |
Gilead Sciences | Maintains: Outperform | 90 100 | 91.85 | 8.87% | 6 | Nov 21, 2024 | |
Cytokinetics | Maintains: Outperform | 99 103 | 48.66 | 111.67% | 6 | Nov 21, 2024 | |
Biogen | Maintains: Outperform | 251 207 | 150.04 | 37.96% | 15 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 113 163 | 87.74 | 85.78% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 25 18 | 10.36 | 73.75% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 223 235 | 270.45 | -13.11% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 34 | 23.25 | 46.24% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 82 99 | 43.75 | 126.29% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 53 | 27.5 | 92.73% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 6 | 1.12 | 435.71% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 21 | 1.61 | 1204.35% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 168 36 | 15.35 | 134.53% | 1 | Nov 16, 2022 |